Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents

Highlights • In RCTs, gliclazide lowered HbA1c more than other oral insulinotropic agents. • Patients taking a DPP-4i or gliclazide have similarly low risks of Hypoglycemia. • National guidelines advocate gliclazide over other SUs for better CV and hypoglycemic safety.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes research and clinical practice 2015-10, Vol.110 (1), p.75-81
Hauptverfasser:	Chan, Siew Pheng, Colagiuri, Stephen
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - epidemiology Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Efficacy Endocrinology & Metabolism Gliclazide Gliclazide - adverse effects Gliclazide - therapeutic use Glyburide - therapeutic use Glycated Hemoglobin A - analysis Humans Hypoglycemia Hypoglycemia - chemically induced Hypoglycemia - epidemiology Hypoglycemic Agents - therapeutic use Insulinotropic Meta-analysis Metformin - therapeutic use Middle Aged Randomized Controlled Trials as Topic - statistics & numerical data Sulfonylurea Compounds - therapeutic use Systematic review Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • In RCTs, gliclazide lowered HbA1c more than other oral insulinotropic agents. • Patients taking a DPP-4i or gliclazide have similarly low risks of Hypoglycemia. • National guidelines advocate gliclazide over other SUs for better CV and hypoglycemic safety.
ISSN:	0168-8227 1872-8227
DOI:	10.1016/j.diabres.2015.07.002